Nosocomial candidiasis: Antifungal stewardship and the importance of rapid diagnosis

Medical Mycology

Volumn 54, Issue 1, 2016, Pages 1-22

  Pfaller, Michael A ^a,b,c,d   Castanheira, Mariana ^b  

^a T2 Biosystems   (United States)

^b JMI LABORATORIES   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Department of Epidemiology   (United States)

Author keywords

Antifungal stewardship; Candida; Rapid diagnostic test; Resistance

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; BLOOD CULTURE; CANDIDIASIS; CULTURE INDEPENDENT DIAGNOSTIC TEST; DIAGNOSTIC TEST; FUNGUS CULTURE; HOSPITAL INFECTION; HUMAN; MORTALITY; NOSOCOMIAL CANDIDIASIS; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PREVALENCE; REVIEW; RISK FACTOR; SPECIES IDENTIFICATION; CANDIDA; CLASSIFICATION; CROSS INFECTION; DRUG EFFECTS; DRUG UTILIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MOLECULAR DIAGNOSIS; PROCEDURES; PROTEOMICS; STANDARDS; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; DRUG UTILIZATION; HUMANS; MICROBIOLOGICAL TECHNIQUES; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEOMICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84971516566     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myv076     Document Type: Review

References (195)

1. Brown GD, Denning DW, Gow NA et al. Hidden killers: human fungal infections. Science translational medicine2012; 4: 165rv13.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
3. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: 325-334.
4. Azie N, Neofytos D, Pfaller M et al. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: Update 2012. Diagn Microbiol Infect Dis 2012; 73: 293-300.
5. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55: 1352-1361.
6. Milazzo L, Peri AM, Mazzali C et al. Candidaemia observed at a university hospital in milan (northern Italy) and review of published studies from 2010 to 2014. Mycopathologia 2014; 178: 227-241.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
8. Pfaller MA, Diekema DJ. The epidemiology of invasive candidasis. In: Calderone RA, Clancy CJ (eds.), Candida and Candidiasis, 2nd ed. Washington, D. C. USA: American Society for Microbiology; 2012: 449-480.
9. Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43: S15-S27.
10. Azoulay E, Dupont H, Tabah A et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 2012; 40: 813-822.
11. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
12. Garey KW, Pai MP, Suda KJ et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007; 16: 919-927.
13. Labelle AJ, Micek ST, Roubinian N et al. Treatment-related risk factors for hospital mortality in Candidabloodstream infections. Crit Care Med 2008; 36: 2967-2972.
14. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candidabloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
15. Parkins MD, Sabuda DM, Elsayed S et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candidaspecies infections. J Antimicrob Chemother 2007; 60: 613-618
16. Taur Y, Cohen N, Dubnow S et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-190.
17. Tabah A, Koulenti D, Laupland K et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 2012; 38: 1930-1945.
18. Drgona L, Khachatryan A, Stephens J et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillusand Candidaspecies. Eur J Clin Microbiol. Infect Dis 2014; 33: 7-21.
19. Lee W, Liew Y, Chlebicki MP et al. An observational study on early empiric versus culture-directed antifungal therapy in critically ill with intra-abdominal sepsis. Crit Care Res Pract 2014; 2014: 479413.
20. Arnold HM, Micek ST, Shorr AF et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010; 30: 361-368.
21. Koehler P, Tacke D, Cornely OA. Our 2014 approach to candidaemia. Mycoses 2014; 57: 581-583.
22. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
23. Arendrup MC, Sulim S, Holm A et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011; 49: 3300-3308.
24. Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Op Infect Dis 2012; 25: 107-115.
25. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA2009; 302: 2323-2329.
26. Chakrabarti A, Sood P, Rudramurthy SM et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015; 41: 285-295.
27. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FK Smutations and elevated minimum inhibitory concentrations. Clin. Infect Dis 2013; 56: 1724-1732.
28. Beyda ND, John J, Kilic A et al. FKS Mutant Candida glabrata: Risk factors and outcomes in patients with candidemia. Clin Infect Dis 2014; 59: 819-825.
29. Pfaller MA, Castanheira M, Lockhart SR et al. Candida glabrata: Multidrug resistance and increased virulence in a major opportunistic fungal pathogen. Curr Fungal Infect Rep 2012; 6: 154-164.
30. Castanheira M, Woosley LN, Messer SA et al. Frequency of fksmutations among Candida glabrataisolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother 2014; 58: 577-580.
31. Pham CD, Iqbal N, Bolden CB et al. The role of FK Smutations in C. glabrata: MIC values, echinocandin resistance and multidrug resistance. Antimicrob Agents Chemother 2014; 58: 4690-4696.
32. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-1302.
33. Pfaller MA, Castanheira M, Lockhart SR et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-1203.
34. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem?Current Op Infect Dis 2014; 27: 484-492.
35. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D et al. Candidaspp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18: 86-90.
36. Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcareassociated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
37. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect. Dis 2001; 33: 177-186.
38. Chen SC, Marriott D, Playford EG et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect 2009; 15: 662-669.
39. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-284.
40. Wenzel RP, Gennings C. Bloodstream infections due to Candidaspecies in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005; 41: S389-S393.
41. Ashley ED, Drew R, Johnson M et al. Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy 2012; 32: 890-901.
42. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: A systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-425.
43. Garey KW, Turpin RS, Bearden DT et al. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: A multi-institutional study. Int J Antimicrob Agents 2007; 29: 557-562.
44. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
45. Hassan I, Powell G, Sidhu M et al. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009; 59: 360-365.
46. Menzin J, Lang KM, Friedman M et al. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER Medicare data. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 2005; 8: 140-148.
47. Menzin J, Meyers JL, Friedman M et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control 2011; 39: e15-20.
48. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-547.
49. Shorr AF, Gupta V, Sun X et al. Burden of early-onset candidemia: Analysis of culture-positive bloodstream infections from a large U. S. database. Crit Care Med 2009; 37: 2519-2526.
50. Wey SB, Mori M, Pfaller MA et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern. Med 1988; 148: 2642-2645.
51. Zilberberg MD, Kollef MH, Arnold H et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study. BMC Infect Dis 2010; 10: 150.
52. Ananda-Rajah MR, Cheng A, Morrissey CO et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother 2011; 55: 1953-1960.
53. Gagne JJ, Breitbart RE, Maio V et al. Costs associated with candidemia in a hospital setting. P&T 2006; 31: 586-619.
54. Fridkin SK. Candidemia is costly-plain and simple. Clin Infect Dis 2005; 41: 1240-2141.
55. Aitken SL, Beyda ND, Shah DN et al. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother 2014; 48: 683-690.
56. Arvanitis M, Anagnostou T, Fuchs BB et al. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 2014; 27: 490-526.
57. Barnes RA, White PL, Bygrave C et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62: 64-69.
58. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56: 1284-1292.
59. Clancy CJ, Nguyen MH. Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev Anti Infect Ther 2014; 12: 731-734.
60. Hull CM, Purdy NJ, Moody SC. Mitigation of humanpathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help?Future Microbiol 2014; 9: 307-325.
61. O'Brien DJ, Gould IM. Maximizing the impact of antimicrobial stewardship: the role of diagnostics, national and international efforts. Current Op Infect Dis 2013; 26: 352-358.
62. Zhang SX. Enhancing molecular approaches for diagnosis of fungal infections. Future Microbiol 2013; 8: 1599-1611.
63. Dellit TH, Owens RC, McGowan JE, Jr. et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177.
64. Leuthner KD, Doern GV. Antimicrobial stewardship programs. J Clin Microbiol 2013; 51: 3916-3920.
65. Ruhnke M. Antifungal stewardship in invasive Candidainfections. Clin Microbiol Infect 2014; 20: 11-18.
66. Standiford HC, Chan S, Tripoli M et al. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012; 33: 338-345.
67. Valerio M, Rodriguez-Gonzalez CG, Munoz P et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 2014; 69: 1993-1999.
68. Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med 2012; 125: S14-24.
69. Perez KK, Olsen RJ, Musick WL et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 2013; 137: 1247-1254.
70. Hanson KE, Pfeiffer CD, Lease ED et al. beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012; 7: e42282.
71. Ostrosky-Zeichner L, Pappas PG, Shoham S et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011; 54: 46-51.
72. Ostrosky-Zeichner L, Shoham S, Vazquez J et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 2014; 58: 1219-1226.
73. Posteraro B, De Pascale G, Tumbarello M et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1->3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care 2011; 15: R249.
74. Apisarnthanarak A, Yatrasert A, Mundy LM, Thammasat University Antimicrobial Stewardship T. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. Infect Control Hosp Epidemiol 2010; 31: 722-727.
75. Reed EE, West JE, Keating EA et al. Improving the management of candidemia through antimicrobial stewardship interventions. Diagn Microbiol Infect Dis 2014; 78: 157-161.
76. Antworth A, Collins CD, Kunapuli A et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacotherapy 2013; 33: 137-143.
77. Guarascio AJ, Slain D, McKnight R et al. A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm 2013; 35: 145-148.
78. Schultz V, Colombo AL, Pasqualotto AC. Invasive candidosis: contrasting the perceptions of infectious disease physicians and intensive care physicians. Rev Soc Bras Med Trop 2013; 46: 466-471.
79. Bauer KA, West JE, Balada-Llasat JM et al. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus blood culture test in patients with S. aureusbacteremia. Clin Infect Dis 2010; 51: 1074-1080.
80. McLintock LA, Jordanides NE, Allan EK et al. The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br J Haematol 2004; 124: 403-404.
81. Caliendo AM, Gilbert DN, Ginocchio CC et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis 2013; 57: S139-170.
82. Nivoix Y, Launoy A, Lutun P et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother 2012; 67: 2506-2513.
83. Cornely OA, Bassetti M, Calandra T et al. ESCMID * guideline for the diagnosis and management of Candidadiseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18: 19-37.
84. Ullmann AJ, Akova M, Herbrecht R et al. ESCMID guideline for the diagnosis and management of Candidadiseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18: 53-67.
85. Mondain V, Lieutier F, Hasseine L et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection 2013; 41: 621-628.
86. Ben-Ami R, Halaburda K, Klyasova G et al. A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease. J Antimicrob Chemother 2013; 68: iii25-33.
87. Cisneros JM, Neth O, Gil-Navarro MV et al. Global impact of an educational antimicrobial stewardship programme on prescribing practice in a tertiary hospital centre. Clin Microbiol Infect 2014; 20: 82-88.
88. Davey P, Brown E, Charani E et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013; 4: CD003543.
89. van Buul LW, Sikkens JJ, van Agtmael MA et al. Participatory action research in antimicrobial stewardship: a novel approach to improving antimicrobial prescribing in hospitals and longterm care facilities. J Antimicrob Chemother 2014; 69: 1734-1741.
90. Craver CW, Tarallo M, Roberts CS et al. Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis. Clin Ther 2010; 32: 2467-2477.
91. Fournier P, Schwebel C, Maubon D et al. Antifungal use influences Candidaspecies distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 2011; 66: 2880-2886.
92. Vandijck D, Blot S, Labeau S et al. Candidemia in critically ill patient: An analysis of daily antifungal therapy related costs. J de Mycologie Medicale 2008; 18: 96-99.
93. Huang AM, Newton D, Kunapuli A et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 2013; 57: 1237-1245.
94. Shah DN, Yau R, Weston J et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66: 2146-2151.
95. MacFadden DR, Leis JA, Mubareka S et al. The opening and closing of empiric windows: the impact of rapid microbiologic diagnostics. Clin Infect Dis 2014; 59: 1199-1200.
96. Wey SB, Mori M, Pfaller MA et al. Risk factors for hospitalacquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-2353.
97. Pfaller MA, Moet GJ, Messer SA et al. Candidabloodstream infections: Comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011; 55: 561-566.
98. Pfaller MA, Neofytos D, Diekema D et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-331.
99. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candidabloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
100. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candidaspp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012; 50: 2846-2856.
101. Schelenz S, Barnes RA, Kibbler CC et al. Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. J Infect 2009; 58: 145-153.
102. Chandrasekar P. Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother 2011; 66: 457-465.
103. Ostrosky-Zeichner L, Marr KA, Rex JH et al. Amphotericin B: time for a new "gold standard". Clin Infect Dis 2003; 37: 415-425.
104. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med 2012; 125: S25-S38.
105. Ostrosky-Zeichner L, Casadevall A, Galgiani JN et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9: 719-727.
106. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicansand the various non-albicans Candidaspp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010; 14: e954-e966.
107. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014; 20: 5-10.
108. Hachem R, Hanna H, Kontoyiannis D et al. The changing epidemiology of invasive candidiasis: Candida glabrataand Candida kruseias the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-2499.
109. Johnson MD, Kleinberg M, Danziger L et al. Pharmacoeconomics of antifungal pharmacotherapy-challenges and future directions. Expert Opin Pharmacother 2005; 6: 2617-2632
110. Maschmeyer G, Patterson TF. Our 2014 approach to breakthrough invasive fungal infections. Mycoses 2014; 57: 645-651.
111. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): Stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-4752.
112. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125: S3-S13.
113. Diekema DJ, Pfaller MA. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004; 25: 624-626.
114. Pfaller MA, Andes DR, Diekema DJ et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candidain 2, 496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One 2014; 9: e101510.
115. Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?Drug Resist Updat 2008; 11: 25-31.
116. Castanheira M, Messer SA, Jones RN et al. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int J Antimicrob Agents 2014; 44: 320-326.
117. Pfaller MA, Jones RN, Castanheira M. Regional data analysis of Candidanon-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 2014; 57: 602-611.
118. Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21: 606-625.
119. Clark TA, Slavinski SA, Morgan J et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosisbloodstream infections in a community hospital. J Clin Microbiol 2004; 42: 4468-4472.
120. Levin AS, Costa SF, Mussi NS et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998; 30: 243-249.
121. Chandra J, Kuhn DM, Mukherjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-5394.
122. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003; 11: 30-36.
123. Pfaller M, Cabezudo I, Koontz F et al. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol 1987; 6: 628-633.
124. Sandford GR, Merz WG, Wingard JR et al. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142: 503-509.
125. Borman AM, Szekely A, Palmer MD et al. Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom. J Clin Microbiol 2012; 50: 2639-2644.
126. Fernandez J, Erstad BL, Petty W et al. Time to positive culture and identification for Candidablood stream infections. Diagn Microbiol Infect Dis 2009; 64: 402-407.
127. Pfaller MA, Woosley LN, Messer SA et al. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia 2012; 174: 259-271.
128. Marcos JY, Pincus DH. Fungal diagnostics: review of commercially available methods. Methods Mol Biol 2013; 968: 25-54.
129. Kathuria S, Singh PK, Sharma C et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 2015; 53: 1823-1830.
130. Buchan BW, Ledeboer NA. Advances in identification of clinical yeast isolates by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2013; 51: 1359-1366.
131. Stone NR, Gorton RL, Barker K et al. Evaluation of PNA-FISH yeast traffic light for rapid identification of yeast directly from positive blood cultures and assessment of clinical impact. J Clin Microbiol 2013; 51: 1301-1302.
132. Hall L, Le Febre KM, Deml SM et al. Evaluation of the Yeast Traffic Light PNA FISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol 2012; 50: 1446-1448.
133. Griffin AT, Hanson KE. Update on fungal diagnostics. Curr Infect Dis Rep 2014; 16: 415.
134. Alexander BD, Ashley ED, Reller LB et al. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 2006; 54: 277-282.
135. Forrest GN, Mankes K, Jabra-Rizk MA et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 2006; 44: 3381-3383.
136. Shields RK, Nguyen MH, Press EG et al. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabratainvasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 2013; 57: 3528-3535.
137. CDC. Antibiotic Resistance Threats in the United States, 2013. www. cdc. gov/drugresistance/threat-report-2013/index. html.
138. Matsumoto E, Boyken L, Tendolkar S et al. Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagn Microbiol Infect Dis 2014; 79: 205-208.
139. Zimbeck AJ, Iqbal N, Ahlquist AM et al. FK Smutations and elevated echinocandin MIC values among Candida glabrata isolates from U. S. population-based surveillance. Antimicrob Agents Chemother 2010; 54: 5042-5047.
140. Sarvikivi E, Lyytikainen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosisstrain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005; 43: 2729-2735.
141. Chong Y, Shimoda S, Yakushiji H et al. Fatal candidemia caused by azole-resistant Candida tropicalisin patients with hematological malignancies. J Infect Chemother 2012; 18: 741-746.
142. Pfaller MA, Rhomberg PR, Messer SA et al. Isavuconazole, micafungin and eight comparator antifungal agents susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: Temporal analysis of antifungal drug resistance using CLSI species-specific interpretive criteria. Diagn Microbiol Infect Dis 2015; 82: 303-313.
143. Garcia-Effron G, Kontoyiannis DP, Lewis RE et al. Caspofungin-resistant Candida tropicalisstrains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 2008; 52: 4181-4813.
144. Jensen RH, Johansen HK, Arendrup MC. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 2013; 57: 614-617.
145. Pasquale T, Tomada JR, Ghannoun M et al. Emergence of Candida tropicalisresistant to caspofungin. J Antimicrob Chemother 2008; 61: 219.
146. Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501-517.
147. Ostrosky-Zeichner L. Candida glabrataand FK Smutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis 2013; 56: 1733-1734.
148. Bae GY, Lee HW, Chang SE et al. Clinicopathologic review of 19 patients with systemic candidiasis with skin lesions. Int J Dermatol 2005; 44: 550-555.
149. Guarner J. Incorporating pathology in the practice of infectious disease: myths and reality. Clin Infect Dis 2014; 59: 1133-1141.
150. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 2011; 24: 247-280.
151. Liesenfeld O, Lehman L, Hunfeld KP et al. Molecular diagnosis of sepsis: New aspects and recent developments. Eur J Microbiol Immunol. (Bp)2014; 4: 1-25.
152. Nguyen MH, Wissel MC, Shields RK et al. Performance of Candidareal-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012; 54: 1240-1248.
153. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2011; 49: 665-670.
154. Neely LA, Audeh M, Phung NA et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Science Translational Medicine 2013; 5: 182ra54.
155. Riedel S, Eisinger SW, Dam L et al. Comparison of BD Bactec Plus Aerobic/F medium to Versa TREK Redox 1 blood culture medium for detection of Candidaspp. in seeded blood culture specimens containing therapeutic levels of antifungal agents. J Clin Microbiol 2011; 49: 1524-1529.
156. Lee A, Mirrett S, Reller LB et al. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 2007; 45: 3546-3548.
157. Meyer MH, Letscher-Bru V, Jaulhac B et al. Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the bactec 9240 system. J Clin Microbiol 2004; 42: 773-777.
158. Mirrett S, Reller LB, Petti CA et al. Controlled clinical comparison of BacT/ALERT standard aerobic medium with BACTEC standard aerobic medium for culturing blood. J Clin Microbiol 2003; 41: 2391-2394.
159. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60: 892-899.
160. Karageorgopoulos DE, Vouloumanou EK, Ntziora F et al. beta D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52: 750-770.
161. Mikulska M, Calandra T, Sanguinetti M et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010; 14: R222.
162. Chang SS, Hsieh WH, Liu TS et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis-a systemic review and meta-analysis. PLoS One 2013; 8: e62323.
163. Carrara L, Navarro F, Turbau M et al. Molecular diagnosis of bloodstream infections with a new dual-priming oligonucleotide-based multiplex PCR assay. J Med Microbiol 2013; 62: 1673-1679.
164. Fitting C, Parlato M, Adib-Conquy M et al. DNAemia detection by multiplex PCR and biomarkers for infection in systemic inflammatory response syndrome patients. PLoS One 2012; 7: e38916.
165. Haag H, Locher F, Nolte O. Molecular diagnosis of microbial aetiologies using Sepsi Test in the daily routine of a diagnostic laboratory. Diagn Microbiol Infect Dis 2013; 76: 413-418.
166. Jordana-Lluch E, Carolan HE, Gimenez M et al. Rapid diagnosis of bloodstream infections with PCR followed by mass spectrometry. PLoS One 2013; 8: e62108.
167. Leitner E, Kessler HH, Spindelboeck W et al. Comparison of two molecular assays with conventional blood culture for diagnosis of sepsis. J Microbiol Methods 2013; 92: 253-255.
168. Loonen AJ, de Jager CP, Tosserams J et al. Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit. PLoS One 2014; 9: e87315.
169. Opota O, Jaton K, Greub G. Microbial diagnosis of bloodstream infection: towards molecular diagnosis directly from blood. Clin Microbiol Infect 2015; 21: 323-331.
170. Schreiber J, Nierhaus A, Braune SA et al. Comparison of three different commercial PCR assays for the detection of pathogens in critically ill sepsis patients. Med Klin Intensivmed Notfmed 2013; 108: 311-318.
171. Wellinghausen N, Kochem AJ, Disque C et al. Diagnosis of bacteremia in whole-blood samples by use of a commercial universal 16S rRNA gene-based PCR and sequence analysis. J Clin Microbiol 2009; 47: 2759-2765.
172. Pittet D, Li N, Woolson RF et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997; 24: 1068-1078.
173. Miller PJ, Wenzel RP. Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections. J Infect Dis 1987; 156: 471-477.
174. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev 2014; 27: 68-88.
175. Pakyz AL, Gurgle HE, Oinonen MJ. Antifungal use in hospitalized adults in U. S. academic health centers. Am J Health Syst Pharm 2011; 68: 415-418.
176. Kollef M, Micek S, Hampton N et al. Septic shock attributed to Candidainfection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54: 1739-1746.
177. Blot SI, Vandewoude KH, Hoste EA et al. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-485.
178. Garrouste-Orgeas M, Timsit JF, Tafflet M et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006; 42: 1118-1126.
179. de With K, Steib-Bauert M, Knoth H et al. Hospital use of systemic antifungal drugs. BMC Clin Pharmacol 2005; 5: 1.
180. Zarb P, Amadeo B, Muller A et al. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect 2012; 18: E389-395.
181. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
182. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
183. Ferrer R, Martin-Loeches I, Phillips G et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749-1755.
184. Investigators TP. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370: 1683-1693.
185. Allou N, Allyn J, Montravers P. When and how to cover for fungal infections in patients with severe sepsis and septic shock. Curr Infect Dis Rep 2011; 13: 426-432.
186. Bassetti M, Righi E, Ansaldi F et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med 2014; 40: 839-845.
187. Gutierrez SM, Heredia M, Gomez E et al. Candidemia in ICU patients with sepsis. Crit Care Med 2013; 41: e385.
188. Guzman JA, Tchokonte R, Sobel JD. Septic shock due to candidemia: outcomes and predictors of shock development. J Clin Med Res 2011; 3: 65-71.
189. Kollef MH, Paiva JA, Charles PE. Candidemia and noncandidemia related septic shock: are there differences between them?Intensive Care Med 2014; 40: 1046-1048.
190. Patel GP, Simon D, Scheetz M et al. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 2009; 16: 508-511.
191. Wisplinghoff H, Seifert H, Wenzel RP et al. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candidaspp. Clin Microbiol Infect 2006; 12: 170-177.
192. Guillamet CV, Vazquez R, Micek ST et al. Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. J Crit Care 2015; 30: 715-720.
193. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.
194. Diekema DJ, Pfaller MA. Rapid detection of antibiotic-resistant organism carriage for infection prevention. Clin Infect Dis 2013; 56: 1614-1620.
195. Bilir SP, Ferrufino CP, Pfaller MA et al. The economic impact of rapid Candida species identification by T2Candida among high-risk patients. Future Microbiol 2015; 10: 1133-1144